- William G. Rice, Ph.D. – President and Chief Executive Officer
- Daniel D. Von Hoff, MD – Co-Founder and Vice President, Medical Affairs
- John K.C. Lim, Pharm.D. – Senior VP, Clinical and Regulatory Affairs
- David M. Ryckman, Ph.D. – Senior VP, Chemistry and Pharmaceutical Operations
- Kenna Anderes, Ph.D. – VP, Cancer Biology
- Claire S. Padgett – VP, Clinical Operations
- Dr. Erich Platzer, M.D. – Chairman of the Board; HBM Partners
- Reinhard J. Ambros, Ph.D. – Managing Director, Novartis BioVenture Fund
- Peter Feinstein - General Partner, BioVentures Investors
- Shaun A. Kirkpatrick – President, Research Corporation Technologies
- Fred A. Middleton – Managing Director, Sanderling Ventures
- S. Edward Torres – Managing Director, Lilly Ventures
- Daniel D. Von Hoff, M.D., F.A.C.P. – Co-Founder and VP, Medical Affairs; University of Arizona
- William G. Rice, Ph.D. – President and Chief Executive Officer
- Jerome Birnbaum, Ph.D. – Principal, Peartree Pharma R&D Consulting
- Brian Druker, M.D. - Professor, Oregon Health & Science University Cancer Center
- Walter Gilbert, Ph.D. – Nobel Laureate and Managing Director, BioVentures Investors
- Ingrid Grummt, Ph.D. - Professor and Division Head, German Cancer Research Center
- Stephen Howell, M.D. - Professor, Moores Cancer Center, University of California, San Diego
- Nancy Maizels, Ph.D. - Professor, University of Washington
- Vincent A. Miller, M.D – Professor, Memorial Sloan Kettering Cancer Center
- Daniel D. Von Hoff, M.D., F.A.C.P. – Cylene Founder; University of Arizona
|
|
